Last reviewed · How we verify
Intradermal vaccine — Competitive Intelligence Brief
marketed
vaccine
Immunology
Biologic
Live · refreshed every 30 min
Target snapshot
Intradermal vaccine (Intradermal vaccine) — Centers for Disease Control and Prevention. Intradermal vaccines deliver immunogenic antigens into the dermis to stimulate local and systemic immune responses with potentially enhanced immunogenicity compared to intramuscular administration.
Comparator set (6 drugs)
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Intradermal vaccine TARGET | Intradermal vaccine | Centers for Disease Control and Prevention | marketed | vaccine | ||
| Comirnaty | BNT162b2 (tozinameran) | Pfizer Inc. | marketed | vaccine | SARS-CoV-2 virus | 2021-08-23 |
| Prevnar 20 | pneumococcal 20-valent conjugate vaccine (PCV20) | Pfizer Inc. | marketed | Pneumococcal conjugate vaccine | Streptococcus pneumoniae capsular polysaccharides (20 serotypes) | 2021-06-08 |
| RSV prefusion F protein-based vaccine | rsv-prefusion-f-protein-based-vaccine | Pfizer Inc. | marketed | Viral protein subunit vaccine | Respiratory syncytial virus fusion (F) protein | |
| Tozinameran 6 months to 4 years of age | tozinameran-6-months-to-4-years-of-age | Pfizer | marketed | vaccine | SARS-CoV-2 spike protein | |
| Tozinameran 12 Years of age and older | tozinameran-12-years-of-age-and-older | Pfizer | marketed | vaccine | SARS-CoV-2 spike protein | |
| Vaccine Support Cp | Vaccine administration | Women and Infants Hospital of Rhode Island | marketed | vaccine | unknown |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
- — Prevnar 20 · US 8,895,024 · Composition of matter · US
- — Prevnar 20 · US 10,279,033 · Method of use · US
Sponsor landscape (vaccine class)
- Pfizer · 20 drugs in this class
- Sanofi Pasteur, a Sanofi Company · 20 drugs in this class
- GlaxoSmithKline · 12 drugs in this class
- Merck Sharp & Dohme LLC · 12 drugs in this class
- Centers for Disease Control and Prevention · 9 drugs in this class
- Zhejiang Provincial Center for Disease Control and Prevention · 7 drugs in this class
- Jiangsu Province Centers for Disease Control and Prevention · 6 drugs in this class
- Beijing Center for Disease Control and Prevention · 6 drugs in this class
- International Centre for Diarrhoeal Disease Research, Bangladesh · 5 drugs in this class
- Sinovac Biotech Co., Ltd · 4 drugs in this class
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Intradermal vaccine CI watch — RSS
- Intradermal vaccine CI watch — Atom
- Intradermal vaccine CI watch — JSON
- Intradermal vaccine alone — RSS
- Whole vaccine class — RSS
Cite this brief
Drug Landscape (2026). Intradermal vaccine — Competitive Intelligence Brief. https://druglandscape.com/ci/intradermal-vaccine. Accessed 2026-05-14.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab